Buy & Sell Uber Technologies Inc (UBER) – Uber Technologies Inc Price Today
Aura AI Summary
Key Stats
- $141.58BMarket Cap
- IndustrialsSector
- -13.34%3M Drawdown
- $147.90BEnterprise Value
- -Dividend Yield
- 48% Buy | 52% SellTrading Activity
- 86 daysTypical Hold Time
Uber Technologies Inc (UBER) is currently valued at a market capitalization of $141.58B, with an enterprise value of $147.90B. Over the past 52 weeks, Uber Technologies Inc has traded between a low of $68.61 and a high of $100.1, highlighting its annual price range. Over the past three months, Uber Technologies Inc has recorded a drawdown of -13.34%, reflecting recent price volatility. On average, investors hold Uber Technologies Inc for approximately 86 days, indicating typical investor behavior on the platform.
About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Most Recent News
US government buys 10% stake in mining firms, signaling a new strategic investment trend.
In early 2026, the US government began acquiring stakes in American mining companies, including a 10% share in USA Rare Earth to support critical mineral projects. This move follows similar investments in Lithium Americas and Trilogy Metals, which sa...

FDA approves Sanofi's Tzield as first disease-modifying therapy for stage 3 type 1 diabetes in children.
The FDA has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). This is the first disease-modifying therapy aimed at delaying the decline of insulin produc...

FDA approves Sanofi's Tzield as first disease-modifying therapy for newly diagnosed stage 3 type 1 diabetes in children.
The FDA granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). Tzield slows the decline of the body's insulin production by targeting the autoimmune process c...
